Secondary Logo

Journal Logo

Most Popular Articles

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes

Tshabalala, Sibongile; Choudhury, Ananyo; Beeton-Kempen, Natasha; More

Pharmacogenetics and Genomics. 29(7):167-178, September 2019.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation

Nenonen, Hannah A.; Lindgren, Ida A.; Prahl, Alexandra S.; More

Pharmacogenetics and Genomics. 29(5):114-120, July 2019.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Girard, Hugo; Court, Michael H; Bernard, Olivier; More

Pharmacogenetics. 14(8):501-515, August 2004.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

Lewis, Joshua P.; Horenstein, Richard B.; Ryan, Kathleen; More

Pharmacogenetics and Genomics. 23(1):1-8, January 2013.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

Zuo, Xiao-cong; Ng, Chee M.; Barrett, Jeffrey S.; More

Pharmacogenetics and Genomics. 23(5):251-261, May 2013.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Griese, Ernst-Ulrich; Ilett, Kenneth F.; Kitteringham, Neil R.; More

Pharmacogenetics. 11(1):69-76, February 2001.

Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function

Leabman, Maya K.; Huang, Conrad C.; Kawamoto, Michiko; More

Pharmacogenetics. 12(5):395-405, July 2002.

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial

Serie, Daniel J.; Crook, Julia E.; Necela, Brian M.; More

Pharmacogenetics and Genomics. 27(10):378-385, October 2017.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

Miller, William R.; Larionov, Alexey A.; Renshaw, Lorna; More

Pharmacogenetics and Genomics. 17(10):813-826, October 2007.

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

Sai, Kimie; Kaniwa, Nahoko; Itoda, Masaya; More

Pharmacogenetics. 13(12):741-757, December 2003.

The role of phase I and II genetic polymorphisms, smoking, alcohol and cancer family history, in the risk of developing testicular cancer

Roco, Angela; Lavanderos, Alejandra; Cayún, Juan P.; More

Pharmacogenetics and Genomics. 29(7):159-166, September 2019.

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

Rotger, Margalida; Colombo, Sara; Furrer, Hansjakob; More

Pharmacogenetics and Genomics. 15(1):1-5, January 2005.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

Haufroid, Vincent; Mourad, Michel; Van Kerckhove, Valérie; More

Pharmacogenetics. 14(3):147-154, March 2004.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer

Ingle, James N.; Kalari, Krishna R.; Momozawa, Yukihide; More

Pharmacogenetics and Genomics. 29(8):183-191, October 2019.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Ekhart, Corine; Doodeman, Valerie D.; Rodenhuis, Sjoerd; More

Pharmacogenetics and Genomics. 18(6):515-523, June 2008.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Niemi, Mikko; Schaeffeler, Elke; Lang, Thomas; More

Pharmacogenetics. 14(7):429-440, July 2004.

A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy

Kiyotani, Kazuma; Uno, Satoko; Mushiroda, Taisei; More

Pharmacogenetics and Genomics. 22(4):229-235, April 2012.

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

Ozdemir, Vural; Bertilsson, Leif; Miura, Jun; More

Pharmacogenetics and Genomics. 17(5):339-347, May 2007.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Suvichapanich, Supharat; Fukunaga, Koya; Zahroh, Hilyatuz; More

Pharmacogenetics and Genomics. 28(7):167-176, July 2018.

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study

Borden, Brittany A.; Galecki, Paige; Wellmann, Rebecca; More

Pharmacogenetics and Genomics. 29(2):31-38, February 2019.

Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene

Damaraju, Sambasivarao; Zhang, Jing; Visser, Frank; More

Pharmacogenetics and Genomics. 15(3):173-182, March 2005.

Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults

Wells, Quinn S.; Veatch, Olivia J.; Fessel, Joshua P.; More

Pharmacogenetics and Genomics. 27(7):247-254, July 2017.

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Tassaneeyakul, Wichittra; Jantararoungtong, Thawinee; Chen, Pei; More

Pharmacogenetics and Genomics. 19(9):704-709, September 2009.

Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population

Kang, Ju-Hee; Chung, Woon-Gye; Lee, Kyung-Hoon; More

Pharmacogenetics. 10(1):67-78, February 2000.

Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose

Dahlman, Ingrid; Vaxillaire, Martine; Nilsson, Maria; More

Pharmacogenetics and Genomics. 18(11):967-975, November 2008.

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)

Fujita, Tomoe; Brown, Chaline; Carlson, Elaine J.; More

Pharmacogenetics and Genomics. 15(4):201-209, April 2005.

Show: